Aditxt Stock In Shambles: Down -55% With 7-Day Losing Streak
Aditxt (ADTX) stock hit day 7 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -55% return. The company has lost about $64538.529999999984 in value over the last 7 days, with its current market capitalization at about $51891.21. The stock remains 99.9% below its value at the end of 2024. This compares with year-to-date returns of 12.3% for the S&P 500.
Aditxt’s stock cratered on investor apprehension following a substantial 1-for-113 reverse split earlier in the month, coupled with a strategic pivot to a blockchain-centric “bitXbio” vision. This sharp shift away from its health innovation roots created market uncertainty, with the new direction failing to inspire confidence among investors.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, ADTX is focused on enhancing immune health through immune mapping and reprogramming, developing products for organ transplantation, skin grafting, autoimmune diseases, and allergy treatments.
Comparing ADTX Stock Returns With The S&P 500
The following table summarizes the return for ADTX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ADTX | S&P 500 |
|---|---|---|
| 1D | -2.8% | 1.0% |
| 7D (Current Streak) | -55.4% | -3.6% |
| 1M (21D) | -91.7% | -2.0% |
| 3M (63D) | -97.6% | 2.5% |
| YTD 2025 | -99.9% | 12.3% |
| 2024 | -99.9% | 23.3% |
| 2023 | -85.6% | 24.2% |
| 2022 | -95.7% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 46 S&P constituents with 3 days or more of consecutive gains and 20 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 10 |
| 4D | 19 | 3 |
| 5D | 1 | 5 |
| 6D | 0 | 0 |
| 7D or more | 3 | 2 |
| Total >=3 D | 46 | 20 |
Key Financials for Aditxt (ADTX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.6 Mil | $0.1 Mil |
| Operating Income | $-26.1 Mil | $-27.9 Mil |
| Net Income | $-32.4 Mil | $-34.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $1,018 | $1,004 |
| Operating Income | $-5.6 Mil | $-6.2 Mil |
| Net Income | $-5.7 Mil | $-7.3 Mil |
The losing streak ADTX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.